PE55398A1 - Composicion farmaceutica para la modulacion inmunitaria - Google Patents
Composicion farmaceutica para la modulacion inmunitariaInfo
- Publication number
- PE55398A1 PE55398A1 PE1997000130A PE00013097A PE55398A1 PE 55398 A1 PE55398 A1 PE 55398A1 PE 1997000130 A PE1997000130 A PE 1997000130A PE 00013097 A PE00013097 A PE 00013097A PE 55398 A1 PE55398 A1 PE 55398A1
- Authority
- PE
- Peru
- Prior art keywords
- adjuvant
- cellular
- mhc
- tumors
- peptides
- Prior art date
Links
- 230000036039 immunity Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000002671 adjuvant Substances 0.000 abstract 3
- 230000001413 cellular effect Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 241001121515 Celes Species 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229920000656 polylysine Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
CARACTERIZADA PORQUE COMPRENDE: (a) UNO O MAS PEPTIDOS CON CAPACIDAD DE FIJACION A UNA O MAS MOLECULAS DEL COMPLEJO DE HISTOCOMPATIBILIDAD (MHC), SIENDO DICHO PEPTIDO UNA PROTEINA INMUNOGENA (VIRAL O BACTERIANA), UN ANTIGENO DE TUMORES O UN PRODUCTO DE DEGRADACION CELULAR DEL MISMO, ENTRE OTROS, EN DONDE SI SE TRATA DE UN ANTIGENO DE TUMORES LA COMPOSICION CONTIENE ADEMAS UNA CITOQUINA; Y (b) UN ADYUVANTE (POLIARGININA O POLILISINA) CONJUGADO CON UN LIGANDO CELULAR (FUCOSA O TRANSFERRINA) COMO COMPONENTE DE UN COMPLEJO DE ADN, EN DONDE EL ADYUVANTE CONTRIBUYE A AUMENTAR LA FIJACION O ENTRADA DEL PEPTIDO A LA CELULA DEL INDIVIDUO A TRATAR. EN ESTA COMPOSICION TOPICA (EN HIDROGEL) o PARENTERAL (EN DONDE EL PEPTIDO ESTA EN FORMA DE SOLUCION O SUSPENSION Y EL ADYUVANTE ES UN SOPORTE PREFERENTEMENTE ACUOSO), LOS PEPTIDOS SON PROCESADOS COMO EXTRANOS POR LAS CELULAS APC`s (CELULAS DENDITRICAS O MACROFAGOS, ENTRE OTROS) Y DESPUES DE SER PRESENTADOS EN EL CONTEXTO DE MHC, A LAS CELULAS INMUNOEFECTORAS, DESENCADENAN O REFUERZAN UNA REACCION INMUNE CELULAR Y/O HUMORAL, PREFERIBLEMENTE SISTEMICA A LAS CELULAS A TRATAR DEL INDIVIDUO, SIENDO UTILES COMO VACUNAS PROFILACTICAS O TERAPEUTICAS, PREFERENTEMENTE PARA TUMORES
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19607044A DE19607044A1 (de) | 1996-02-24 | 1996-02-24 | Tumorvakzine und Verfahren zu ihrer Herstellung |
DE19638313A DE19638313C2 (de) | 1996-09-19 | 1996-09-19 | Pharmazeutische Zusammensetzung für die Immunmodulation |
DE19648687A DE19648687A1 (de) | 1996-11-25 | 1996-11-25 | Pharmazeutische Zusammensetzung für die Immunmodulation |
Publications (1)
Publication Number | Publication Date |
---|---|
PE55398A1 true PE55398A1 (es) | 1998-09-22 |
Family
ID=27215945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1997000130A PE55398A1 (es) | 1996-02-24 | 1997-02-24 | Composicion farmaceutica para la modulacion inmunitaria |
Country Status (35)
Country | Link |
---|---|
US (1) | US7105162B1 (es) |
EP (1) | EP0881906B2 (es) |
JP (1) | JP4184433B2 (es) |
KR (1) | KR100457647B1 (es) |
CN (1) | CN1177610C (es) |
AR (1) | AR005945A1 (es) |
AT (1) | ATE274350T1 (es) |
AU (1) | AU722264B2 (es) |
BG (1) | BG63682B1 (es) |
BR (1) | BR9707694A (es) |
CA (1) | CA2243559C (es) |
CO (1) | CO4600681A1 (es) |
CZ (1) | CZ295396B6 (es) |
DE (1) | DE59711873D1 (es) |
DK (1) | DK0881906T4 (es) |
EE (1) | EE04481B1 (es) |
ES (1) | ES2225951T5 (es) |
HK (1) | HK1017257A1 (es) |
HR (1) | HRP970100B1 (es) |
HU (1) | HU224410B1 (es) |
ID (1) | ID16038A (es) |
IL (1) | IL125361A (es) |
MY (1) | MY119276A (es) |
NO (1) | NO983850L (es) |
NZ (1) | NZ332020A (es) |
PE (1) | PE55398A1 (es) |
PL (1) | PL189413B1 (es) |
PT (1) | PT881906E (es) |
RO (1) | RO119344B1 (es) |
RS (1) | RS50101B (es) |
SI (1) | SI0881906T2 (es) |
SK (1) | SK284582B6 (es) |
TR (1) | TR199801649T2 (es) |
TW (1) | TW585774B (es) |
WO (1) | WO1997030721A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS50101B (sr) | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
ES2289200T3 (es) * | 1998-02-25 | 2008-02-01 | The Government Of The United States, As Represented By The Secretary Of The Army | Uso de mejoradores para penetracion de la piel y agentes de alteracion de barrera para mejorar la respuesta inmune transcutanea. |
EP1071411B1 (en) * | 1998-04-20 | 2007-03-14 | Torrey Pines Institute For Molecular Studies | Topical immunostimulation to induce langerhans cell migration |
EP2204186B1 (en) * | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
DE19909503A1 (de) * | 1999-03-04 | 2000-09-07 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
US6809179B1 (en) | 1999-08-04 | 2004-10-26 | Boehringer Ingelheim International Gmbh | Tumor-associated antigen (R11) |
AT408721B (de) * | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
AT409085B (de) * | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
AT409762B (de) * | 2000-04-13 | 2002-11-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung von zytokin sekretierenden zellen |
AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
KR20020014459A (ko) * | 2000-08-18 | 2002-02-25 | 서진호 | 양이온성 아미노산이 부가된 융합단백질 및 이를 이용한생물공정의 개선방법 |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
JP2004519452A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
JP2004519453A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
FR2824326B1 (fr) * | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
CA2452909A1 (en) * | 2001-12-07 | 2003-06-13 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
AU2003258672B2 (en) | 2002-09-13 | 2008-10-30 | Intercell Ag | Method for isolating hepatitis C virus peptides |
WO2004035618A2 (en) | 2002-10-15 | 2004-04-29 | Intercell Ag | Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
CN1756843B (zh) | 2003-03-04 | 2012-03-21 | 英特塞尔股份公司 | 化脓链球菌抗原 |
EP1608402B1 (en) | 2003-03-24 | 2010-10-20 | Intercell AG | Improved vaccines |
WO2004087746A2 (en) | 2003-03-31 | 2004-10-14 | Intercell Ag | Staphylococcus epidermidis antigens |
CA2522238A1 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
AU2004235952A1 (en) | 2003-05-07 | 2004-11-18 | Intercell Ag | Streptococcus agalactiae antigens I + II |
CN102304527A (zh) | 2003-05-30 | 2012-01-04 | 英特塞尔股份公司 | 肠球菌抗原 |
ATE489967T1 (de) | 2003-07-11 | 2010-12-15 | Intercell Ag | Hcv-vakzin |
ES2297688T3 (es) | 2004-03-12 | 2008-05-01 | Intercell Ag | Procedimiento para solubizar mezclas de peptidos. |
DE102004038134B4 (de) | 2004-08-05 | 2013-07-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung |
ES2344739T3 (es) | 2004-09-24 | 2010-09-06 | Intercell Ag | Proteina capsidial vp1 modificada del parvovirus b19. |
ES2327432T3 (es) * | 2004-10-29 | 2009-10-29 | Intercell Ag | Vacunas contra el vhc para pacientes con vhc cronica. |
US7785612B2 (en) * | 2005-04-20 | 2010-08-31 | Taiho Pharmaceutical Co., Ltd. | Polyamino acid for use as adjuvant |
EP1887084A1 (en) * | 2006-08-10 | 2008-02-13 | International Investment and Patents SA | Plasmids with immunological action |
EP2059526A2 (en) | 2006-09-15 | 2009-05-20 | Intercell AG | Borrelia antigens |
JP2008174490A (ja) * | 2007-01-18 | 2008-07-31 | Nitto Denko Corp | 抗原性ペプチドを主成分とする薬剤 |
CA2685805A1 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
KR100748265B1 (ko) * | 2007-06-15 | 2007-08-10 | (주)성문엔지니어링 | 공동주택에 배선된 전선의 합선방지구조 |
EP2511291A3 (en) | 2007-06-18 | 2012-11-07 | Intercell AG | Chlamydia antigens |
WO2009016639A2 (en) | 2007-08-02 | 2009-02-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
ES2703571T3 (es) * | 2008-03-27 | 2019-03-11 | Nestec Sa | Métodos para aumentar la absorción de péptidos, peptidomiméticos y otros sustratos de proteína de transporte gastrointestinal |
CN102239253A (zh) | 2008-12-03 | 2011-11-09 | 普罗蒂亚维仕尼科技有限公司 | 谷氨酰tRNA合成酶(GtS)片段 |
US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
EP2470205A1 (en) * | 2009-08-27 | 2012-07-04 | Novartis AG | Adjuvant comprising aluminium, oligonucleotide and polycation |
WO2011057131A1 (en) | 2009-11-09 | 2011-05-12 | Spotlight Technology Partners Llc | Polysaccharide based hydrogels |
US8795727B2 (en) | 2009-11-09 | 2014-08-05 | Spotlight Technology Partners Llc | Fragmented hydrogels |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
WO2011101465A1 (en) | 2010-02-19 | 2011-08-25 | Intercell Ag | Ic31 nanoparticles |
US9303070B2 (en) | 2011-02-22 | 2016-04-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
RU2478399C2 (ru) * | 2011-06-16 | 2013-04-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных Российской академии сельскохозяйственных наук (ГНУ ВНИИБТЖ Россельхозакадемии) | Способ получения специфического иммуномодулятора |
US20140271723A1 (en) * | 2013-03-15 | 2014-09-18 | Saint Louis University | Adjuvant compositions and methods of using thereof |
EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
CN109072227A (zh) * | 2016-03-15 | 2018-12-21 | 组库创世纪株式会社 | 用于免疫治疗的监测和诊断及治疗剂的设计 |
EP3463440A4 (en) * | 2016-05-27 | 2020-04-15 | Etubics Corporation | NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF |
WO2018070069A1 (ja) * | 2016-10-11 | 2018-04-19 | サイトリミック株式会社 | 医薬 |
CN107469067B (zh) * | 2017-09-05 | 2018-06-19 | 浙江大学 | 一种多肽及其改造体在制备免疫调节药物中的应用 |
MA52363A (fr) | 2018-04-26 | 2021-03-03 | Agenus Inc | Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation |
CN110870912A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 亚甲蓝类染料作为疫苗佐剂的应用、包含该佐剂的疫苗及其应用 |
CN110870913A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1290141A (es) | 1968-05-31 | 1972-09-20 | ||
US4847240A (en) * | 1978-01-16 | 1989-07-11 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
US4728639A (en) * | 1982-07-27 | 1988-03-01 | University Of Tennessee Research Corporation | Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant |
US6022544A (en) * | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US4956273A (en) * | 1985-10-24 | 1990-09-11 | Southwest Foundation For Biomedical Research | Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC |
BE1000587A4 (fr) | 1986-06-13 | 1989-02-14 | Oncogen | Coordinats et procedes en vue d'augmenter la proliferation des lymphocytes b. |
GB2220939B (en) * | 1988-06-10 | 1992-02-26 | Medical Res Council | Peptide fragments of hiv and their use in vaccines and diagnosis |
EP0440742B1 (en) * | 1988-10-27 | 1997-01-15 | The Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
US5480967A (en) | 1990-01-05 | 1996-01-02 | United Biomedical, Inc. | HIV-1 core protein fragments |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
ES2221920T3 (es) | 1992-04-03 | 2005-01-16 | The Regents Of The University Of California | Sistema de liberacion de polinucleotidos de autoensamblaje que comprende un peptido cationico anfipatico. |
ES2225824T3 (es) | 1992-08-31 | 2005-03-16 | Ludwig Institute For Cancer Research | Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos. |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
US5409703A (en) * | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
CZ3000U1 (cs) | 1993-07-12 | 1995-02-22 | Kufudakis Alekos | Farmaceutický prostředek pro imunomodulační a adjuvantní léčbu |
JP2828391B2 (ja) * | 1993-10-29 | 1998-11-25 | 東燃株式会社 | オリゴ糖を表面に有するリポソーム |
US6660276B1 (en) * | 1994-02-16 | 2003-12-09 | The University Of Virginia Patent Foundation | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor |
US6001809A (en) * | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
UY24367A1 (es) † | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
RS50101B (sr) | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
-
1997
- 1997-02-20 RS YUP-62/97A patent/RS50101B/sr unknown
- 1997-02-20 CO CO97009092A patent/CO4600681A1/es unknown
- 1997-02-21 MY MYPI97000683A patent/MY119276A/en unknown
- 1997-02-21 EE EE9800255A patent/EE04481B1/xx unknown
- 1997-02-21 DE DE59711873T patent/DE59711873D1/de not_active Expired - Lifetime
- 1997-02-21 IL IL12536197A patent/IL125361A/en not_active IP Right Cessation
- 1997-02-21 PT PT97905068T patent/PT881906E/pt unknown
- 1997-02-21 AU AU18759/97A patent/AU722264B2/en not_active Ceased
- 1997-02-21 CZ CZ19982689A patent/CZ295396B6/cs not_active IP Right Cessation
- 1997-02-21 DK DK97905068T patent/DK0881906T4/da active
- 1997-02-21 JP JP52980697A patent/JP4184433B2/ja not_active Expired - Fee Related
- 1997-02-21 SI SI9730672T patent/SI0881906T2/sl unknown
- 1997-02-21 BR BR9707694A patent/BR9707694A/pt not_active IP Right Cessation
- 1997-02-21 WO PCT/EP1997/000828 patent/WO1997030721A1/de active IP Right Grant
- 1997-02-21 HR HR970100A patent/HRP970100B1/xx not_active IP Right Cessation
- 1997-02-21 TR TR1998/01649T patent/TR199801649T2/xx unknown
- 1997-02-21 AT AT97905068T patent/ATE274350T1/de active
- 1997-02-21 US US09/125,672 patent/US7105162B1/en not_active Expired - Fee Related
- 1997-02-21 HU HU9901186A patent/HU224410B1/hu not_active IP Right Cessation
- 1997-02-21 CA CA2243559A patent/CA2243559C/en not_active Expired - Fee Related
- 1997-02-21 PL PL97328455A patent/PL189413B1/pl unknown
- 1997-02-21 EP EP97905068A patent/EP0881906B2/de not_active Expired - Lifetime
- 1997-02-21 AR ARP970100701A patent/AR005945A1/es active IP Right Grant
- 1997-02-21 SK SK1145-98A patent/SK284582B6/sk not_active IP Right Cessation
- 1997-02-21 ES ES97905068T patent/ES2225951T5/es not_active Expired - Lifetime
- 1997-02-21 KR KR10-1998-0706339A patent/KR100457647B1/ko not_active IP Right Cessation
- 1997-02-21 RO RO98-01305A patent/RO119344B1/ro unknown
- 1997-02-21 NZ NZ332020A patent/NZ332020A/en not_active IP Right Cessation
- 1997-02-21 CN CNB971925186A patent/CN1177610C/zh not_active Expired - Fee Related
- 1997-02-24 ID IDP970541A patent/ID16038A/id unknown
- 1997-02-24 PE PE1997000130A patent/PE55398A1/es not_active IP Right Cessation
- 1997-02-24 TW TW086102221A patent/TW585774B/zh not_active IP Right Cessation
-
1998
- 1998-08-21 BG BG102714A patent/BG63682B1/bg active Active
- 1998-08-21 NO NO983850A patent/NO983850L/no not_active Application Discontinuation
-
1999
- 1999-05-25 HK HK99102360A patent/HK1017257A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE55398A1 (es) | Composicion farmaceutica para la modulacion inmunitaria | |
AR127116A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
ES2158943T3 (es) | Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos. | |
DE60029460D1 (de) | Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon | |
ES2181752T3 (es) | Conjugados de agentes antitumorales de metiltritio y productos intermedios para su sintesis. | |
ES2107051T3 (es) | Formulaciones de proteinas de liberacion sostenida. | |
DE69733247D1 (de) | Humanisiertes grünes-fluoreszenzprotein und methoden | |
RU2003114434A (ru) | Вакцинная композиция | |
AR086511A2 (es) | Agentes de union especifica al factor de crecimiento de hepatocitos | |
ZA975851B (en) | Hepatocyte grown factor receptor agonists and uses thereof | |
TR199902818T2 (xx) | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. | |
HRP20110981T1 (hr) | Tumoru pridruženi peptidi koji se slobodno vežu na molekule ljudskog leukocitnog antigena (hla) klasa ii | |
ES2165653T3 (es) | Equipo ciclador termico. | |
DE69713112D1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen | |
EA200100749A1 (ru) | Синтетические пептиды, обладающие поверхностной активностью, и их применение для приготовления синтетического сурфактанта | |
BR9708220A (pt) | Peptìdios de ligação hla-a2.1 e seus usos | |
PE20081004A1 (es) | Agentes inductores de muerte celular | |
NO963919D0 (no) | Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler | |
CY1110235T1 (el) | Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων | |
RU98111622A (ru) | Противоопухолевая вакцина и способ ее получения | |
WO2020191415A8 (en) | Compositions and methods for treating diseases and disorders associated with aberrant regulation of proteins | |
AR241794A1 (es) | Procedimiento para obtener inteerleucina-2 humana, en una celula de ovario de hamster de la china. | |
BR0212070A (pt) | ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica | |
EP1812035A4 (en) | PEPTIDE ANTITUMOR AGENT | |
AU7615900A (en) | Isolated peptides which bind to mhc class ii molecules, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
MK | Expiration of term |